BioXcel receives Nasdaq deficiency notices for bid price and market value; faces delisting risk

BioXcel Therapeutics, Inc.

On Sep 16, 2024, Nasdaq notified BTAI that bid price closed below $1.00 for 30 consecutive business days.
Company has until March 17, 2025 to regain compliance; stock must close at $1.00+ for 10 consecutive days.
On Sep 20, 2024, Nasdaq notified BTAI that market value of listed securities fell below $35M minimum.
Compliance deadline for market value is March 19, 2025; must meet $35M+ for 10 consecutive days.
BTAI evaluating options; cannot assure regaining compliance; may be eligible for second 180-day period.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.